Hartwig Medical Foundation
- Algorithms
- Billing code
- Biomarker
- Cancer of Unknown Primary
- cfDNA
- DNA
- Education
- End of Treatment
- GENAYA project
- Hartwig Medical Database
- Hartwig Medical Foundation
- Innovation
- IT
- Lab process
- Learning healthcare system
- Molecular diagnostics
- OncoAct
- Participating hospitals
- Patients' stories
- Personalized treatment
- Quality
- Rare cancers
- Re-use data
- Research
- Scientific publications
- Uncategorized
- Whole genome sequencing
- Working in the cloud
From Spreadsheets to Digital Convenience: Hartwig Goes Live With Its Customer Portal
Hartwig Medical Foundation (Hartwig) recently launched its new portal for submitting requests for WGS analysis. For hospitals, this is an important enhancement to …
GMS and Hartwig sign MOU to advance precision medicine for cancer patients
Genomic Medicine Sweden (GMS) and Hartwig Medical Foundation (Hartwig) today signed a Memorandum of Understanding (MoU). This MoU formalises a strategic partnership …
GENAYA Extended: More Care and Research
The GENAYA project has been extended by two years. This gives researchers more time to collect genetic tumor data from …
From innovation to standard care: real-world impact of whole genome sequencing in oncology
Whole genome sequencing (WGS) is rapidly transforming cancer diagnostics. The Netherlands Cancer Institute (NKI) has already integrated this technology into …
Comprehensive molecular diagnostics closer for more patients thanks to price reduction
Hartwig Medical Foundation reduces the price of its OncoAct Whole Genome Sequencing (WGS) service as of January 1, 2026. This …
Whole genome sequencing: the future of molecular diagnostics in gynecological cancer?
To mark Gynecological Oncology Awareness Month, we spoke with oncologist Eelke Gort about the role of molecular diagnostics in these …
GLOW Study Ends – But WGS Remains Valuable for Glioblastoma Patients
As of October 1, 2025, the GLOW study will officially come to an end. Interim analysis has shown growing enthusiasm …
Hartwig Medical Foundation welcomes new managing director
Hartwig Medical Foundation is pleased to announce that Robert Jan Lamers has joined the organization as its new managing director, …
Dutch Healthcare Institute approves reimbursement of whole genome sequencing (WGS) for targeted cancer treatment
The Dutch National Health Care Institute (Zorginstituut Nederland, ZiNL) has approved the reimbursement of whole genome sequencing (WGS) through the …
First time linking Hartwig Medical Database with the Netherlands Cancer Registry for AYA Patients
This July, the first data transfer was completed between the Netherlands Cancer Registry (NKR) and the Hartwig Medical Database for …
Clinical Trials Day and the importance of structurally recording treatment outcomes
Today, on Clinical Trials Day (May 20), we reflect on the importance of clinical research. For Hartwig, it’s a opportunity …
Automatically the right trial and treatment with ACTIN: A new step in cancer care
Imagine you have a patient with cancer sitting across from you: can’t be cured, but he is determined to try …
Blogs
Listening, connecting, and building bridges to make more impact for patients with cancer
This is how Robert Jan Lamers describes his role as managing director of Hartwig Medical Foundation. For four months now, …
Read more
Medicines Policy must be based on real world data
The recent decision by the National Health Care Institute to re-evaluate expensive cancer medicines in real-world practice is a logical …
Read more
Cancer, a rare disease?
It may come as a surprise to many on this International Rare Disease Day (February 28), that a significant number …
Read moreVideos
From biopsy to patient report
The comprehensive DNA test can provide patients with cancer with more opportunities for treatment. Using the technique of Whole Genome …
Read more
What does Hartwig Medical Foundation do?
Hartwig Medical Foundation is a unique initiative that makes possible progress in the research of treatment of cancer in the …
Read more
It is important to unravel the DNA in rare types of cancer; 21% of patients with cancer have a rare form.